JP2024505790A - インテグリンアルファ１１ベータ１に対する抗体 - Google Patents

インテグリンアルファ１１ベータ１に対する抗体 Download PDF

Info

Publication number
JP2024505790A
JP2024505790A JP2023536875A JP2023536875A JP2024505790A JP 2024505790 A JP2024505790 A JP 2024505790A JP 2023536875 A JP2023536875 A JP 2023536875A JP 2023536875 A JP2023536875 A JP 2023536875A JP 2024505790 A JP2024505790 A JP 2024505790A
Authority
JP
Japan
Prior art keywords
antibody
antigen
seq
binding fragment
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536875A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505790A5 (https=
Inventor
クラタジック，エルマ
ダブリュ． メドール，スリー，ジェームス
ベネデュース，クリストファー
Original Assignee
モメンタ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モメンタ ファーマシューティカルズ インコーポレイテッド filed Critical モメンタ ファーマシューティカルズ インコーポレイテッド
Publication of JP2024505790A publication Critical patent/JP2024505790A/ja
Publication of JP2024505790A5 publication Critical patent/JP2024505790A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023536875A 2020-12-18 2021-12-17 インテグリンアルファ１１ベータ１に対する抗体 Pending JP2024505790A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063127849P 2020-12-18 2020-12-18
US63/127,849 2020-12-18
US202163213973P 2021-06-23 2021-06-23
US63/213,973 2021-06-23
PCT/IB2021/061926 WO2022130318A2 (en) 2020-12-18 2021-12-17 Antibodies against integrin alpha 11 beta 1

Publications (2)

Publication Number Publication Date
JP2024505790A true JP2024505790A (ja) 2024-02-08
JP2024505790A5 JP2024505790A5 (https=) 2024-12-25

Family

ID=79021748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536875A Pending JP2024505790A (ja) 2020-12-18 2021-12-17 インテグリンアルファ１１ベータ１に対する抗体

Country Status (13)

Country Link
US (1) US20240317865A1 (https=)
EP (1) EP4263605A2 (https=)
JP (1) JP2024505790A (https=)
KR (1) KR20230121831A (https=)
AU (1) AU2021400221A1 (https=)
BR (1) BR112023011777A2 (https=)
CA (1) CA3205574A1 (https=)
CL (1) CL2023001757A1 (https=)
CO (1) CO2023008544A2 (https=)
IL (1) IL303741A (https=)
MX (1) MX2023007302A (https=)
TW (1) TW202241946A (https=)
WO (1) WO2022130318A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127500A1 (en) 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019154961A1 (en) * 2018-02-08 2019-08-15 Bergen Teknologioverføring As Antibody against alpha-11 integrin and its use
WO2019168176A1 (ja) * 2018-03-01 2019-09-06 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79289A (en) 1985-07-05 1992-01-15 Whitehead Biomedical Inst Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
ATE117375T1 (de) 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
JP2914692B2 (ja) 1987-12-11 1999-07-05 ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ 内皮細胞の遺伝子修飾
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2096750T3 (es) 1990-10-31 1997-03-16 Somatix Therapy Corp Vectores retroviricos utiles para la terapia genica.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6146361A (en) 1996-09-26 2000-11-14 Becton Dickinson And Company Medication delivery pen having a 31 gauge needle
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
US6192891B1 (en) 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
US6277099B1 (en) 1999-08-06 2001-08-21 Becton, Dickinson And Company Medication delivery pen
WO2003022330A2 (en) 2001-09-12 2003-03-20 Becton, Dickinson And Company Microneedle-based pen device for drug delivery and method for using same
FR2849436B1 (fr) 2002-12-27 2007-01-05 Patrick Frayssinet Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
WO2021127500A1 (en) * 2019-12-20 2021-06-24 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019154961A1 (en) * 2018-02-08 2019-08-15 Bergen Teknologioverføring As Antibody against alpha-11 integrin and its use
WO2019168176A1 (ja) * 2018-03-01 2019-09-06 国立大学法人広島大学 抗インテグリンα１１モノクローナル抗体、およびその利用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCERS, vol. vol.11(6), 765, JPN6025047306, 2019, ISSN: 0005738230 *
MABS, vol. 12, no. 1, JPN6025047307, 24 January 2020 (2020-01-24), pages 1717265, ISSN: 0005738229 *

Also Published As

Publication number Publication date
AU2021400221A1 (en) 2023-07-13
MX2023007302A (es) 2023-09-04
US20240317865A1 (en) 2024-09-26
KR20230121831A (ko) 2023-08-21
AU2021400221A9 (en) 2025-03-13
WO2022130318A3 (en) 2022-08-04
EP4263605A2 (en) 2023-10-25
BR112023011777A2 (pt) 2023-10-03
CL2023001757A1 (es) 2024-01-05
CA3205574A1 (en) 2022-06-23
WO2022130318A2 (en) 2022-06-23
IL303741A (en) 2023-08-01
CO2023008544A2 (es) 2023-07-10
TW202241946A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
JP6840127B2 (ja) がんの治療における抗ｐｄ−１抗体および抗ｍ−ｃｓｆ抗体の併用
US20260042845A1 (en) Antibodies against integrin alpha 11 beta 1
JP2020520912A (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
JPWO2005027970A1 (ja) 癌治療用医薬
JP2024518776A (ja) 抗ａｄｇｒｅ２抗体及びその使用
US12600784B2 (en) Anti-Clec12A antibodies and uses thereof
JP7829595B2 (ja) 補体因子ｄを標的とする抗体及びその使用
JP2024505790A (ja) インテグリンアルファ１１ベータ１に対する抗体
US20230250182A1 (en) Methods for treating cancer or von-hippel lindau disease using a combination of a pd-1 antagonist, a hif-2 alpha inhibitor, and lenvatinib or a pharmaceutically acceptable salt thereof
EP3618869A1 (en) COMPOSITIONS AND METHODS RELATED TO xCT ANTIBODIES
EA048635B1 (ru) Антитела против интегрина альфа 11 бета 1
US12110325B2 (en) TM4SF5-targeting humanized antibody and use thereof
JP7769635B2 (ja) 抗ｃｄ１９抗体及びその使用
RU2844463C1 (ru) Способы лечения рака или болезни фон-гиппеля-линдау с использованием комбинации антагониста pd-1, ингибитора hif-2 альфа и ленватиниба или его фармацевтически приемлемой соли
CN117222666A (zh) 抗整联蛋白α11β1抗体
WO2019020734A1 (en) ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENTS IN CARDIOVASCULAR DISEASES
JP2025523477A (ja) インテグリンアルファ１１ベータ１に対する抗体及びその使用
WO2025106725A2 (en) HUMAN ANTI-α5β1 ANTIBODIES AND USES THEREOF
EA051556B1 (ru) Антитела к adgre2 и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225